Ismael Galve-Roperh

Ismael Galve-Roperh

Auto-generated profile, based on publicly available information

Ismael Galve-Roperh

Department of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica (IUIN), Complutense University, Madrid, Spain

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2009 in Brain
Verified
Journal Article
Open access
PDF file
JPJavier Palazuelos
Javier Palazuelos
TATania Aguado
Tania Aguado
MPM. Ruth Pazos
M. Ruth Pazos
BJBoris Julien
Boris Julien
CCCarolina Carrasco
Carolina Carrasco
IGIsmael Galve-Roperh
Ismael Galve-Roperh
Cannabinoid-derived drugs are promising agents for the development of novel neuroprotective strategies. Activation of neuronal CB1 cannabinoid receptors attenuates excitotoxic glutamatergic neurotransmission, triggers prosurvival signalling pathways and palliates motor symptoms in animal models of neurodegenerative disorders. However, in Huntington's disease there is a very early downregulation of CB1 receptors in striatal neurons that, together with the undesirable psychoactive effects triggered by CB1 receptor activation, foster the search for alternative pharmacological treatments. Here, we show that CB2 cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients. Genetic ablation of CB2 receptors in R6/2 mice, that express human mutant huntingtin exon 1, enhanced microglial activation, aggravated disease symptomatology and reduced mice lifespan. Likewise, induction of striatal excitotoxicity in CB2 receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration. Moreover, administration of CB2 receptor-selective agonists to wild-type mice subjected to excitotoxicity reduced neuroinflammation, brain oedema, striatal neuronal loss and motor symptoms. Studies on ganciclovir-induced depletion of astroglial proliferation in transgenic mice expressing thymidine kinase under the control of the glial fibrillary acidic protein promoter excluded the participation of proliferating astroglia in CB2 receptor-mediated actions. These findings support a pivotal role for CB2 receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington's disease as well as in other neurodegenerative disorders with a significant excitotoxic component.

24 June 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Jan MulderJan Mulder
Jan Mulder
TATania Aguado
Tania Aguado
Erik KeimpemaErik Keimpema
Erik Keimpema
KBKlaudia Barabás
Klaudia Barabás
CRCarlos J. Ballester Rosado
Carlos J. Ballester Rosado
THTibor Harkany
Tibor Harkany
Endocannabinoids (eCBs) have recently been identified as axon guidance cues shaping the connectivity of local GABAergic interneurons in the developing cerebrum. However, eCB functions during pyramidal cell specification and establishment of long-range axonal connections are unknown. Here, we show that eCB signaling is operational in subcortical proliferative zones from embryonic day 12 in the mouse telencephalon and controls the proliferation of pyramidal cell progenitors and radial migration of immature pyramidal cells. When layer patterning is accomplished, developing pyramidal cells rely on eCB signaling to initiate the elongation and fasciculation of their long-range axons. Accordingly, CB 1 cannabinoid receptor (CB 1 R) null and pyramidal cell-specific conditional mutant (CB 1 R f/f,NEX-Cre ) mice develop deficits in neuronal progenitor proliferation and axon fasciculation. Likewise, axonal pathfinding becomes impaired after in utero pharmacological blockade of CB 1 Rs. Overall, eCBs are fundamental developmental cues controlling pyramidal cell development during corticogenesis.

1 July 2013 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
ACAlline C. Campos
Alline C. Campos
ZOZaira Ortega
Zaira Ortega
JPJavier Palazuelos
Javier Palazuelos
MFManoela V. Fogaça
Manoela V. Fogaça
DADaniele C. Aguiar
Daniele C. Aguiar
FGFrancisco S. Guimarães
Francisco S. Guimarães
Cannabidiol (CBD), the main non-psychotomimetic component of the plant Cannabis sativa, exerts therapeutically promising effects on human mental health such as inhibition of psychosis, anxiety and depression. However, the mechanistic bases of CBD action are unclear. Here we investigate the potential involvement of hippocampal neurogenesis in the anxiolytic effect of CBD in mice subjected to 14 d chronic unpredictable stress (CUS). Repeated administration of CBD (30 mg/kg i.p., 2 h after each daily stressor) increased hippocampal progenitor proliferation and neurogenesis in wild-type mice. Ganciclovir administration to GFAP-thymidine kinase (GFAP-TK) transgenic mice, which express thymidine kinase in adult neural progenitor cells, abrogated CBD-induced hippocampal neurogenesis. CBD administration prevented the anxiogenic effect of CUS in wild type but not in GFAP-TK mice as evidenced in the novelty suppressed feeding test and the elevated plus maze. This anxiolytic effect of CBD involved the participation of the CB1 cannabinoid receptor, as CBD administration increased hippocampal anandamide levels and administration of the CB1–selective antagonist AM251 prevented CBD actions. Studies conducted with hippocampal progenitor cells in culture showed that CBD promotes progenitor proliferation and cell cycle progression and mimics the proliferative effect of CB1 and CB2 cannabinoid receptor activation. Moreover, antagonists of these two receptors or endocannabinoid depletion by fatty acid amide hydrolase overexpression prevented CBD-induced cell proliferation. These findings support that the anxiolytic effect of chronic CBD administration in stressed mice depends on its proneurogenic action in the adult hippocampus by facilitating endocannabinoid-mediated signalling.

1 October 2013 in Progress in Lipid Research
Verified
Journal Article
Closed access
IGIsmael Galve-Roperh
Ismael Galve-Roperh
Valerio ChiurchiùValerio Chiurchiù
Valerio Chiurchiù
JDJavier Díaz-Alonso
Javier Díaz-Alonso
MBMonica Bari
Monica Bari
MGManuel Guzmán
Manuel Guzmán
MMMauro Maccarrone
Mauro Maccarrone

1 February 2006 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
TATania Aguado
Tania Aguado
JPJavier Palazuelos
Javier Palazuelos
KMKrisztina Monory
Krisztina Monory
NSNephi Stella
Nephi Stella
BCBenjamin Cravatt
Benjamin Cravatt
IGIsmael Galve-Roperh
Ismael Galve-Roperh
Endocannabinoids exert an important neuromodulatory role via presynaptic cannabinoid CB1receptors and may also participate in the control of neural cell death and survival. The function of the endocannabinoid system has been extensively studied in differentiated neurons, but its potential role in neural progenitor cells remains to be elucidated. Here we show that the CB1receptor and the endocannabinoid-inactivating enzyme fatty acid amide hydrolase are expressed, bothin vitroandin vivo, in postnatal radial glia (RC2+cells) and in adult nestin type I (nestin+GFAP+) neural progenitor cells. Cell culture experiments show that CB1receptor activation increases progenitor proliferation and differentiation into astroglial cellsin vitro.In vivoanalysis evidences that, in postnatalCB1−/−mouse brain, progenitor proliferation and astrogliogenesis are impaired. Likewise, in adult CB1-deficient mice, neural progenitor proliferation is decreased but is increased in fatty acid amide hydrolase-deficient mice. In addition, endocannabinoid signaling controls neural progenitor differentiation in the adult brain by promoting astroglial differentiation of newly born cells. These results show a novel physiological role of endocannabinoids, which constitute a new family of signaling cues involved in the regulation of neural progenitor cell function.

2 October 2006 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JPJavier Palazuelos
Javier Palazuelos
TATania Aguado
Tania Aguado
AEAinara Egia
Ainara Egia
RMRaphael Mechoulam
Raphael Mechoulam
MGManuel Guzmán
Manuel Guzmán
IGIsmael Galve‐Roperh
Ismael Galve‐Roperh
Cannabinoids, the active components of marijuana and their endogenous counterparts, act on the brain and many other organs through the widely expressed CB 1 cannabinoid receptor. In contrast, the CB 2 cannabinoid receptor is abundant in the immune system and shows a restricted expression pattern in brain cells. CB 2 ‐selective agonists are, therefore, very attractive therapeutic agents as they do not cause CB 1 ‐mediated psychoactive effects. CB 2 receptor expression in brain has been partially examined in differentiated cells, while its presence and function in neural progenitor cells remain unknown. Here we show that the CB 2 receptor is expressed, both in vitro and in vivo , in neural progenitors from late embryonic stages to adult brain. Selective pharmacological activation of the CB 2 receptor in vitro promotes neural progenitor cell proliferation and neurosphere generation, an action that is impaired in CB 2 ‐deficient cells. Accordingly, in vivo experiments evidence that hippocampal progenitor proliferation is increased by administration of the CB 2 ‐selective agonist HU‐308. Moreover, impaired progenitor proliferation was observed in CB 2 ‐deficient mice both in normal conditions and on kainate‐induced excitotoxicity. These findings provide a novel physiological role for the CB 2 cannabinoid receptor and open a novel therapeutic avenue for manipulating neural progenitor cell fate.—Palazuelos, J., Aguado, T., Egia, A., Mechoulam, R., Guzmán, M., Galve‐Roperh, I. Non‐psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 20, E1773–E1779 (2006)